A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Three-Way Crossover Study to Evaluate the Safety, Tolerability and Clinical Activity of ASM-024 Administered by Inhalation Once Daily to Subjects With Mild Allergic Asthma.

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Three-Way Crossover Study to Evaluate the Safety, Tolerability and Clinical Activity of ASM-024 Administered by Inhalation Once Daily to Subjects With Mild Allergic Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 May 2013

At a glance

  • Drugs ASM 024 (Primary)
  • Indications Allergic asthma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 May 2013 Results presented at the 109th International Conference of the American Thoracic Society.
    • 16 May 2013 Results presented at 2013 American Thoracic Society (ATS) International Conference.
    • 25 Jan 2012 Actual end date (January 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top